Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name (Ascending) Strength SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
00143-9098-01 00143-9098 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 27, 2022 In Use
00409-1700-01 00409-1700 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 27, 2022 In Use
00781-3258-70 00781-3258 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous May 31, 2022 In Use
68001-0541-36 68001-0541 Bortezomib Bortezomib 3.5 mg/3.5mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 31, 2022 In Use
70511-0161-05 70511-0161 Bortezomib Bortezomib 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Aug. 11, 2022 In Use
70511-0162-02 70511-0162 Bortezomib Bortezomib 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Aug. 11, 2022 In Use
71288-0118-10 71288-0118 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 26, 2022 In Use
72205-0183-01 72205-0183 Bortezomib Bortezomib 3.5 mg/3.5mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 27, 2022 In Use
72266-0243-01 72266-0243 Bortezomib Bortezomib 1.0 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Aug. 23, 2022 In Use
72266-0244-01 72266-0244 Bortezomib Bortezomib 2.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Aug. 23, 2022 In Use
68001-0534-36 68001-0534 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 31, 2022 April 29, 2025 In Use
83090-0008-01 83090-0008 Bortezomib Bortezomib 3.5 mg/3.5mL Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 15, 2023 In Use
43598-0865-60 43598-0865 Bortexomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous Nov. 1, 2019 In Use
31722-0303-31 31722-0303 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 3, 2024 In Use
72338-0200-01 72338-0200 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous June 19, 2018 In Use
43598-0426-60 43598-0426 Bortexomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous July 26, 2022 In Use
70860-0225-10 70860-0225 Bortezomib Bortezomib 3.5 mg/1 Chemotherapy Proteasome Inhibitor 26S Intravenous, Subcutaneous May 6, 2022 In Use
63539-0117-01 63539-0117 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00069-0135-01 00069-0135 Bosutinib monohydrate, Bosutinib Bosulif 100.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00069-0136-01 00069-0136 Bosutinib monohydrate, Bosutinib Bosulif 500.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 4, 2012 In Use
00574-0106-01 00574-0106 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 1, 2014 In Use
00574-0106-03 00574-0106 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral April 1, 2014 In Use
00781-2119-01 00781-2119 Bromocriptine Mesylate Bromocriptine Mesylate Chemotherapy Dopamine Agonist Ergot Derivative Oral June 28, 1978 Nov. 30, 2013 No Longer Used
00781-2119-31 00781-2119 Bromocriptine Mesylate Bromocriptine Mesylate Chemotherapy Dopamine Agonist Ergot Derivative Oral June 28, 1978 Nov. 30, 2013 No Longer Used
00781-5325-01 00781-5325 Bromocriptine Mesylate Bromocriptine Mesylate 2.5 mg/1 Chemotherapy Dopamine Agonist Ergot Derivative Oral Jan. 13, 1998 In Use

Found 10,000 results in 5 milliseconds — Export these results